[1]Szulc, P. and P.D. Delmas.Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis.[J].Osteoporos Int, 2008, 19(12):1683-1704
[2]张青,赵蓓初,李建力.唑来膦酸的药理作用及临床应用[J].实用临床医药杂志, 2006, 10(4):132-134
[3]Epstein S .Update of current therapeutic options for the treatment of postmenopausal osteoporosis.[J].Clin Ther, 2006, 28(2):151-173
[4]Reid, I.R., et al.Intravenous zoledronic acid in postmenopausal women with low bone mineral density.[J].N Engl J Med, 2002, 346(9):653-661
[5]Basso, F.G., et al..Zoledronic acid inhibits human osteoblast activities.[J].Gerontology, 2013, 59(6):534-541
[6]甘莉.密固达在骨质疏松症中的疗效及其对骨代谢相关指标的影响观察[J].海南医学院学报, 2013, 19(8):1077-1083
[7]Catalano, A, et al..Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.[J].J Clin Endocrinol Metab, 2013, 98(5):1911-1915
[8]Black, D.M., et al..Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.[J].N Engl J Med, 2007, 356(18):1809-1822
[9]McClung, M, et al..Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.[J].Obstet Gynecol, 2009, 114(5):999-1007
[10]Recker, R.R., et al..Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.[J].J Bone Miner Res, 2008, 23(1):6-16
[11]Neville-Webbe, Hand R.E. Coleman.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.[J].Palliat Med, 2003, 17(6):539-553
[12]袁元杏等.唑来膦酸钠应用近期安全性观察[J].中国骨质疏松杂志, 2012, 18(10):921-924
[13]娄振凯等.注射用唑来膦酸治疗绝经后骨质疏松36例[J].中国新药与临床杂志, 2012, 31(5):247-250
[14]Green, J.R., et al..Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models.[J].Pharmacol Toxicol, 1997, 80(5):225-230
[15]Boonen, S, et al..Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.[J].Kidney Int, 2008, 74(5):641-648
[16]贾秀娟等.高龄老年骨质疏松症患者应用唑来膦酸注射液的安全性及疗效初步分析[J].中国骨质疏松杂志, 2013, 19(10):1080-1083 |